Table 1. Baseline characteristics by study groups.
| Virologic rebound (n = 5) | Virologic control (n = 67) | P value* | |
| Age, y (SD) | 47.0 (6,3) | 46.8 (10.6) | 0.97 |
| Male, No (%) | 5 (100) | 56 (84) | 1.0 |
| Cohort, No (%) | |||
| POSOVIR | 2 (40) | 50 (75) | 0.13 |
| REACH | 3 (60) | 17 (25) | |
| Race, No (%) | |||
| Caucasian | 4 (75) | 61 (91) | 0.41 |
| Black | 1 (25) | 6 (9) | |
| CD4 cell count, mean (SD) | 478 (310) | 532 (223) | 0.62 |
| CD4 cell nadir, mean (SD) | 188 (139) | 233 (175) | 0.57 |
| Prior exposure to NNRTI in months, mean (SD) | 28.4 (22.9) | 30,5 (28,0) | 0.88 |
| Prior suboptimal nucleoside exposure, No (%) | 1 (20) | 24 (36) | 0.48 |
| Current NNRTI, No (%) | |||
| Nevirapine | 4 (80) | 56 (84) | 1.0 |
| Efavirenz | 1 (20) | 11 (16) | |
| Daily dosage, No (%) | |||
| Once-daily | 2 (40) | 27 (40) | 1.0 |
| Twice daily | 3 (60) | 40 (60) | |
*
Exact Fisher chi-square test for percentages and t-test for continuous variables.